Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder

Neuropsychopharmacology

Volumn 33, Issue 11, 2008, Pages 2551-2565

  Quiroz, Jorge A ^a   Gray, Neil A ^a,b   Kato, Tadafumi ^c   Manji, Husseini K ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Columbia University ^*  (United States)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

bcl 2; Bipolar disorder; Calcium regulation; Lithium; Mitochondria; Synaptic plasticity

Indexed keywords

CALCIUM; LITHIUM; PROTEIN BCL 2;

BIPOLAR DISORDER; BRAIN MITOCHONDRION; CELL PROTECTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE EXPRESSION; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; NERVE CELL PLASTICITY; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BIPOLAR DISORDER; HUMANS; MITOCHONDRIA; NEURONAL PLASTICITY; TREATMENT OUTCOME;

EID: 51749121067     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301671     Document Type: Review

References (134)

1. Bachmann RF, Schloesser RJ, Gould TD, Manji HK (2005). Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol Neurobiol 32: 173-202.
2. Balijepalli S, Boyd MR, Ravindranath V (1999). Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology 38: 567-577.
3. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB (1996). Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport 7: 1397-1400.
4. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M et al (2007). Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 62: 7-16.
5. Ben-Shachar D, Zuk R, Gazawi H, Reshef A, Sheinkman A, Klein E (1999). Increased mitochondrial complex I activity in platelets of schizophrenic patients. Int J Neuropsychopharmcol 2: 245-253.
6. Benes FM, Matzilevich D, Burke RE, Walsh J (2006). The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry 11: 241-251.
7. Berk M, Bodemer W, van Oudenhove T, Butkow N (1994). Dopamine increases platelet intracellular calcium in bipolar affective disorder and controls. Int Clin Psychopharmacol 9: 291-293.
8. Bernardi P, Colonna R, Costantini P, Eriksson O, Fontaine E, Ichas F et al (1998). The mitochondrial permeability transition. Biofactors 8: 273-281.
9. Bertolino A, Frye M, Callicott JH, Mattay VS, Rakow R, Shelton-Repella J et al (2003). Neuronal pathology in the hippocampal area of patients with bipolar disorder: a study with proton magnetic resonance spectroscopic imaging. Biol Psychiatry 53: 906-913.
10. Bijur GN, Jope RS (2003). Glycogen synthase kinase-3beta is highly activated in nuclei and mitochondria. Neuroreport 14: 2415-2419.
11. Billups B, Forsythe ID (2002). Presynaptic mitochondrial calcium sequestration influences transmission at mammalian central synapses. J Neurosci 22: 5840-5847.
12. Bothwell RA, Eccleston D, Marshall E (1994). Platelet intracellular calcium in patients with recurrent affective disorders. Psychopharmacology (Berl) 114: 375-381.
13. Bowden CL, Huang LG, Javors MA, Johnson JM, Seleshi E, McIntyre K et al (1988). Calcium function in affective disorders and healthy controls. Biol Psychiatry 23: 367-376.
14. Catts VS, Catts SV, Fernandez HR, Taylor JM, Coulson EJ, Lutze-Mann LH et al (2005). A microarray study of post-mortem mRNA degradation in mouse brain tissue. Post-mortem interval effects on the phosphorylation of signaling proteins. Brain Res Mol Brain Res 138: 164-177.
15. Cavelier L, Jazin EE, Eriksson I, Prince J, Bave U, Oreland L et al (1995). Decreased cytochrome-c oxidase activity and lack of age-related accumulation of mitochondrial DNA deletions in the brains of schizophrenics. Genomics 29: 217-224.
16. Cecil KM, DelBello MP, Morey R, Strakowski SM (2002). Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord 4: 357-365.
17. Chalmers S, Nicholls DG (2003). The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. J Biol Chem 278: 19062-19070.
18. Chang K, Adleman N, Dienes K, Barnea-Goraly N, Reiss A, Ketter T (2003). Decreased N-acetylaspartate in children with familial bipolar disorder. Biol Psychiatry 53: 1059-1065.
19. Chang K, Barnea-Goraly N, Karchemskiy A, Simeonova DI, Barnes P, Ketter T et al (2005). Cortical magnetic resonance imaging findings in familial pediatric bipolar disorder. Biol Psychiatry 58: 197-203.
20. Chen CL, Lin CF, Chiang CW, Jan MS, Lin YS (2006). Lithium inhibits ceramide- and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Mol Pharmacol 70: 510-517.
21. Chen G, Zeng WZ, Yuan P, Huang LD, Jiang YM, Zhao ZH et al (1999). The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72: 879-882.
22. Chen RW, Chuang DM (1999). Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression: a prominent role in neuroprotection against excitotoxicity. J Biol Chem 274: 6039-6042.
23. Chuang DM, Priller J (2006). Potential use of lithium in neurodegenerative disorders. In: Bauer M, Grof P, Muller-Oerlinghausen B (eds). Lithium in Neuropsychiatry: the Comprehensive Guide. Informa UK Ltd: Abingdon: Oxon. pp 381-398.
24. Cui J, Shao L, Young LT, Wang JF (2007). Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144: 1447-1553.
25. Culmsee C, Mattson MP (2005). p53 in neuronal apoptosis. Biochem Biophys Res Commun 331: 761-777.
26. de Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G et al (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 8: 195-208.
27. Deicken RF, Fein G, Weiner MW (1995). Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am J Psychiatry 152: 915-918.
28. Deicken RF, Pegues MP, Anzalone S, Feiwell R, Soher B (2003). Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. Am J Psychiatry 160: 873-882.
29. DePaulo Jr JR (2004). Genetics of bipolar disorder: where do we stand? Am J Psychiatry 161: 595-597.
30. Dimauro S, Mancuso M, Naini A (2004). Mitochondrial encephalomyopathies: therapeutic approach. Ann NY Acad Sci 1011: 232-245.
31. Drevets WC (2000). Neuroimaging studies of mood disorders. Biol Psychiatry 48: 813-829.
32. Drevets WC, Ryan CM, Bogers WD, Birmaher B, Axelson D, Dahl RE (2004). Subgenual prefrontal cortex volume decreased in healthy humans at high familial risk for mood disorders. Society for Neuroscience. Washington, DC: Program No. 799.19.
33. Dror N, Klein E, Karry R, Sheinkman A, Kirsh Z, Mazor M et al (2002). State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia. Mol Psychiatry 7: 995-1001.
34. Dubovsky SL, Christiano J, Daniell LC, Franks RD, Murphy J, Adler L et al (1989). Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 46: 632-638.
35. Dubovsky SL, Lee C, Christiano J, Murphy J (1991). Elevated platelet intracellular calcium concentration in bipolar depression. Biol Psychiatry 29: 441-450.
36. Dubovsky SL, Murphy J, Thomas M, Rademacher J (1992). Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 149: 118-120.
37. Dubovsky SL, Thomas M, Hijazi A, Murphy J (1994). Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci 243: 229-234.
38. Emamghoreishi M, Schlichter L, Li PP, Parikh S, Sen J, Kamble A et al (1997). High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry 154: 976-982.
39. Fadic R, Johns DR (1996). Clinical spectrum of mitochondrial diseases. Semin Neurol 16: 11-20.
40. 2+ response in neutrophils from patients under chronic lithium therapy. Eur Arch Psychiatry Clin Neurosci 243: 240-243.
41. Glazner GW, Chan SL, Lu C, Mattson MP (2000). Caspase-mediated degradation of AMPA receptor subunits: a mechanism for preventing excitotoxic necrosis and ensuring apoptosis. J Neurosci 20: 3641-3649.
42. Goodwin FK, Jamison KR (2007). Manic-Depressive Illness: Bipolar Disorder and Recurrent Depression Vol 2nd edn. Oxford University Press: New York.
43. Gould TD, Manji HK (2002). The Wnt signaling pathway in bipolar disorder. Neuroscientist 8: 497-511.
44. Gould TD, Quiroz JA, Singh JB, Zarate Jr CA, Manji HK (2004). Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 9: 734-755.
45. Hamakawa H, Kato T, Murashita J, Kato N (1998). Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci 248: 53-58.
46. Hamakawa H, Murashita J, Yamada N, Inubushi T, Kato N, Kato T (2004). Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin Neurosci 58: 82-88.
47. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM (2002). Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 80: 589-597.
48. Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM (2002). Differential hippocampal expression of glutamic Acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 59: 521-529.
49. Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S et al (1996). Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci USA 93: 2719-2723.
50. Hough C, Lu SJ, Davis CL, Chuang DM, Post RM (1999). Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry 46: 247-255.
51. Hovatta I, Tennant RS, Helton R, Marr RA, Singer O, Redwine JM et al (2005). Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 438: 662-666.
52. Iosifescu DV, Renshaw PE (2003). 31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioenergetic mechanism in depression? Harv Rev Psychiatry 11: 51-63.
53. Iwamoto K, Bundo M, Kato T (2005). Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Gemt 14: 241-253.
54. Jope RS (2003). Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24: 441-443.
55. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW et al (2004). Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549.
56. Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I et al (2003). Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat Genet 35: 171-175.
57. Kandel ER, Schwartz JH, Jessell TM (2000). Principles of Neural Sciences 4th edn. McGraw-Hill: New York, NY.
58. Karry R, Klein E, Ben Shachar D (2004). Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry 55: 676-684.
59. 2+ signalling in transformed lymphoblastoid cells from patients with bipolar disorder. Int J Neuropsychopharmacol 6: 379-389.
60. Kato T, Kato N (2000). Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2: 180-190.
61. Kato T, Kunugi H, Nanko S, Kato N (2001). Mitochondrial DNA polymorphisms in bipolar disorder. J Affect Disord 62: 151-164.
62. Kato T, Murashita J, Kamiya A, Shioiri T, Kato N, Inubushi T (1998). Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity. Eur Arch Psychiatry Clin Neurosci 248: 301-306.
63. Kato T, Shioiri T, Murashita J, Hamakawa H, Takahashi Y, Inubushi T et al (1995). Lateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS. Psychol Med 25: 557-566.
64. Kato T, Takahashi S, Shioiri T, Inubushi T (1992). Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord 26: 223-230.
65. Kim H, McGrath BM, Silverstone PH (2005). A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders - focus on magnetic resonance spectroscopy (MRS) studies. Hum Psychopharmacol Clin Exp 20: 309-326.
66. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S (2004). Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 61: 300-308.
67. Kusumi I, Koyama T, Yamashita I (1992). Thrombin-induced platelet calcium mobilization is enhanced in bipolar disorders. Biol Psychiatry 32: 731-734.
68. Kusumi I, Koyama T, Yamashita I (1994). Serotonin-induced platelet intracellular calcium mobilization in depressed patients. Psychopharmacology (Berl) 113: 322-327.
69. Kusumi I, Suzuki K, Sasaki Y, Kameda K, Koyama T (2000). Treatment response in depressed patients with enhanced Ca mobilization stimulated by serotonin. Neuropsychopharmacology 23: 690-696.
70. Lai JS, Zhao C, Warsh JJ, Li PP (2006). Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol 539: 18-26.
71. Li J, Gould TD, Yuan P, Manji HK, Chen G (2003). Post-mortem interval effects on the phosphorylation of signaling proteins. Neuropsychopharmacology 28: 1017-1025.
72. Li J, Vawter MP, Walsh DM, Tomita H, Evans SJ, Choudary PV et al (2004). Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 13: 609-616.
73. Liang M-H, Chuang DM (2007). Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 282: 3904-3917.
74. Linseman DA, Butts BD, Precht TA, Phelps RA, Le SS, Laessig TA et al (2004). Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci 24: 9993-10002.
75. Manji HK, Moore GJ, Chen G (1999). Lithium at 50: have the neuroprotective effects of this unique cation been overlooked. Biol Psychiatry 46: 929-940.
76. Manji HK, Moore GJ, Chen G (2000a). Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 48: 740-754.
77. Manji HK, Moore GJ, Chen G (2000b). Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 61(Suppl 9): 82-96.
78. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray NA et al (2003). Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53: 707-742.
79. Mattson MP, Gary DS, Chan SL, Duan W (2001). Perturbed endoplasmic reticulum function, synaptic apoptosis and the pathogenesis of Alzheimer's disease. Biochem Soc Symp 67: 151-162.
80. Mattson MP, Liu D (2003). Mitochondrial potassium channels and uncoupling proteins in synaptic plasticity and neuronal cell death. Biochem Biophys Res Commun 304: 539-549.
81. Maurer I, Zierz S, Moller H (2001). Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr Res 48: 125-136.
82. McMahon FJ, Stine OC, Meyers DA, Simpson SG, DePaulo JR (1995). Patterns of maternal transmission in bipolar affective disorder. Am J Hum Genet 56: 1277-1286.
83. Modica-Napolitano JS, Lagace CJ, Brennan WA, Aprille JR (2003). Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch Pharm Res 26: 951-959.
84. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB et al (2000). Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 48: 1-8.
85. Moore GJ, Cortese BM, Glitz DA, Zajac-Benitez C, Quiroz JA, Uhede TW et al (2005). Lithium increases gray matter in the preformtal and subgenual preforntal cortices in treatment responsive bipolar disorder patients. ACNP 44th Annual Meeting. Waikoloa, Hawaii.
86. Murashita J, Kato T, Shioiri T, Inubushi T, Kato N (2000). Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31P-MR spectroscopy. Psychol Med 30: 107-115.
87. Murphy AN, Bredesen DE, Cortopassi G, Wang E, Fiskum G (1996). Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci USA 93: 9893-9898.
88. Murphy E (2004). Inhibit GSK-3beta or there's heartbreak dead ahead. J Clin Invest 113: 1526-1528.
89. Naydenov AV, MacDonald ML, Ongur D, Konradi C (2007). Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch Gen Psychiatry 64: 555-564.
90. Nicholls DG, Ward MW (2000). Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts. Trends Neurosci 23: 166-174.
91. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F et al (2005). Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102: 6990-6995.
92. Okamoto Y, Kagaya A, Shinno H, Motohashi N, Yamawaki S (1995). Serotonin-induced platelet calcium mobilization is enhanced in mania. Life Sci 56: 327-332.
93. Pae CU, Choe BY, Joo RH, Lim HK, Kim TS, Yoo SS et al (2004). Neuronal dysfunction of the frontal lobe in schizophrenia. Neuropsychobiology 50: 211-215.
94. Pan T, Li X, Xie W, Jankovic J, Le W (2005). Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett 579: 6716-6720.
95. Perera TD, Coplan JD, Lisanby SH, Lipira CM, Arif M, Carpio C et al (2007). Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci 27: 4894-4901.
96. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423: 435-439.
97. Prince J, Blennow K, Gottfries CG, Karlsson I, Oreland L (1999). Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology 21: 372-379.
98. Quiroz JA, Singh JB, Gould TD, Denicoff K, Zarate, Jr CA. et al (2004). Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Mol Psychiatry 9: 756-776.
99. Rajkowska G (2000). Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 48: 766-777.
100. Ren M, Senatorov VV, Chen RW, Chuang DM (2003). Post-insult treatment with lithium reduces brain damage and facilitates neurological recovery in a rat ischemia/reperfusion model. Proc Natl Acad Sci USA 100: 6210-6215.
101. Richter C, Park JW, Ames BN (1988). Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 85: 6465-6467.
102. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB et al (2007). Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27: 1981-1991.
103. Rowland L, Bustillo JR, Lauriello J (2001). Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin Clin Neuropsychiatry 6: 121-130.
104. Sapolsky RM (2000). The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 48: 755-765.
105. Sassi RB, Brambilla P, Hatch JP, Nicoletti M, Mallinger AG, Frank E et al (2004). Reduced left anterior cingulate volumes in untreated bipolar patients. Biol Psychiatry 56: 467-475.
106. Sassi RB, Nicoletti M, Brambilla P, Mallinger AG, Frank E, Kupfer DJ et al (2002). Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 329: 243-245.
107. Schloesser RJ, Song J, Klein PS, Manji HK (2007). Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology Rev e-pub ahead of print, October 3, 2007; doi:10.1038/sj.npp.1301575.
108. Shao L, Young LT, Wang JF (2005). Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 58: 879-884.
109. 2+ responses in rat oligodendrocyte progenitors. J Physiol 508: 413-426.
110. Sokolov BP, Jiang L, Trivedi NS, Aston C (2003). Transcription profiling reveals mitochondrial, ubiquitin and signaling systems abnormalities in postmortem brains from subjects with a history of alcohol abuse or dependence. J Neurosci Res 72: 756-767.
111. Stine OC, Xu J, Koskela R, McMahon FJ, Gschwend M, Friddle C et al (1995). Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. Am J Hum Genet 57: 1384-1394.
112. Stork C, Renshaw PE (2005). Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 10: 900-919.
113. Stout AK, Raphael HM, Kanterewicz BI, Klann E, Reynolds JJ (1998). Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat Neurosci 1: 366-373.
114. Sun X, Wang JF, Tseng M, Young LT (2006). Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 31: 189-196.
115. Suzuki K, Kusumi I, Sasaki Y, Koyama T (2001). Serotonin-induced platelet intracellular calcium mobilization in various psychiatric disorders: is it specific to bipolar disorder. J Affect Disord 64: 291-296.
116. Tan CH, Javors MA, Seleshi E, Lowrimore PA, Bowden CL (1990). Effects of lithium on platelet ionic intracellular calcium concentration in patients with bipolar (manic-depressive) disorder and healthy controls. Life Sci 46: 1175-1180.
117. Tan CH, Lee HS, Kua EH, Peh LH (1995). Resting and thrombin-stimulated cytosolic calcium in platelets of patients with alcoholic withdrawal, bipolar manic disorder and chronic schizophrenia. Life Sci 56: 1817-1823.
118. Theberge J, Al-Semaan Y, Drost DJ, Malla AK, Neufeld RW, Bartha R et al (2004). Duration of untreated psychosis vs N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla. Psychiatry Res 131: 107-114.
119. Torok TL (1989). Neurochemical transmission and the sodium-pump. Prog Neurobiol 32: 11-76.
120. 2+ response in neutrophils of manic-depressive patients: effect of lithium therapy. Neuropsychobiology 27: 180-183.
121. Vawter MP, Tomita H, Meng F, Bolstad B, Li J, Choudary PV et al (2006). Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry 11: 663-679.
122. Volz HP, Rzanny R, Riehemann S, May S, Hegewald H, Preussler B et al (1998). 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci 248: 289-295.
123. Washizuka S, Kakiuchi C, Mori K, Kunugi H, Tajima O, Akiyama T et al (2003). Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder. Am J Med Genet 120B: 72-78.
124. Weeber EJ, Levy M, Sampson MJ, Anflous K, Armstrong DL, Brown SE et al (2002). The role of mitochondrial porins and the permeability transition pore in learning and synaptic plasticity. J Biol Chem 277: 18891-18897.
125. Williams JM, Thompson VL, Mason-Parker SE, Abraham WC, Tate WP (1998). Synaptic activity-dependent modulation of mitochondrial gene expression in the rat hippocampus. Brain Res Mol Brain Res 60: 50-56.
126. Winsberg ME, Sachs N, Tate DL, Adalsteinsson E, Spielman D, Ketter TA (2000). Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry 47: 475-481.
127. 2+-dependent regulator protein. J Biol Chem 252: 4108-4117.
128. Xu J, Culman J, Blume A, Brecht S, Gohlke P (2003). Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke 34: 1287-1292.
129. Yamawaki S, Kagaya A, Okamoto Y, Shimizu M, Nishida A, Uchitomi Y (1996). Enhanced calcium response to serotonin in platelets from patients with affective disorders. J Psychiatry Neurosci 21: 321-324.
130. 2+ exchanger and protein kinase C. J Cell Biol 163: 511-523.
131. Yeste M, Alvira D, Verdaguer E, Tajes M, Folch J, Rimbau V et al (2007). Evaluation of acute antiapoptotic effects of Li+ in neuronal cell cultures. J Neural Transm 114: 405-416.
132. Yildiz-Yesiloglu A, Ankerst DP (2006). Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 147: 1-25.
133. Yoon IS, Li PP, Siu KP, Kennedy JL, Macciardi F, Cooke RG et al (2001). Altered TRPC7 gene expression in bipolar-I disorder. Biol Psychiatry 50: 620-626.
134. Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G (1998). Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16: 2265-2282.